Peter Rahmer - 29 Jan 2024 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
Title: Chief Corporate Development Officer
Signature
/s/ Thomas Catinazzo, as Attorney-in-Fact
Issuer symbol
RLAY
Transactions as of
29 Jan 2024
Net transactions value
-$15,916
Form type
4
Filing time
31 Jan 2024, 16:14:06 UTC
Previous filing
18 Jan 2024
Next filing
29 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Sale $15,916 -1,651 -0.32% $9.64 514,977 29 Jan 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,506 shares of restricted stock units ("RSUs") on January 27, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
F2 Includes 471,840 shares underlying RSUs.

Remarks:

Title: Chief Corporate Development Officer